Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure

Breast Cancer Clinical Trial

— ULTIMATE  

Official title:

A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02997995
• Other study ID #: UC-0140/1606
• Secondary ID: UCBG-105BIG 16-0
• Status: Completed
• Phase: Phase 2
• Start date: February 15, 2017
• Est. completion date: August 28, 2020

Study information

• Verified date: September 2020
• Source: UNICANCER
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, multicentric, international, phase II trial testing aromatase inhibitors in combination with durvalumab in patients with CD8+ T cell infiltration (>10% CD8+ T cells in the tumor). The trial includes two sequences: The first part of the treatment will consist in 4-6 weeks treatment with immune-attractants; in the second part, CD8+ patients will receive 6 months of durvalumab combined with exemestane.

Description:

The study is conducted in 2 parts:

Part 1: lymphocyte attraction. After the screening phase, the patient will receive immune-attractant combined with exemestane for six weeks.

As immune-attractants are added over the course of the study, they will appear as subsequent appendices in the full protocol.

Up to 4 cohorts may be tested sequentially in this design until up to 240 evaluable patients have been treated.

The first cohort of patients will receive tremelimumab (3 mg/kg, single infusion) combined with exemestane (25 mg daily). In each cohort, an interim analysis will be performed after 30 patients in order to potentially stop the cohort (if less than 25% of patients present >10% CD8+ cells in the tumor after 3 weeks). If all 4 cohorts are closed and the target number of 56 patients for part 2 has not been reached, additional patients will be recruited and treated with the best performing immune-attractant treatment based on the part I results. From the moment 56 patients are included in part 2, no more patients will be entered in part 1.

After three weeks (+/- 3 days), a tumor biopsy will be done. Patients who present >10% CD8+ cells in the tumor after 3 weeks and remain eligible will be included in the second part of the trial (patients who do not present CD8+ T cells on the 3-week biopsy will be treated at the investigator's choice).

Part 2: lymphocyte activation (anti-PD1 treatment) Four to six weeks after immune-attractant start, patients having >10% CD8+ cells in the tumor will receive durvalumab 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months.

Part 2 will include two steps. In the first step, we will include 23 patients. If 2 or more pathological complete responses are observed in these 23 patients, the part 2 will move to step 2. 33 additional patients will be included in the step 2.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 61
• Est. completion date: August 28, 2020
• Est. primary completion date: July 15, 2019
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age =18 years post-menopausal according to one of the following criteria:

• Age >60 years

• Or Bilateral ovariectomy

• Or Age =60, with an uterus and presenting an amenorrhea of more than 12 months and FSH and estradiol in the postmenopausal range

• Or Age =60, without an uterus and FSH and estradiol in the postmenopausal range

2. Histologically proven invasive breast cancer eligible to neoadjuvant endocrine therapy according to multidisciplinary tumor board.

Note: Multicentric/multifocal tumors are allowed if all share the same characteristics

3. cT2-T4, any N; cT2 are eligible only if the clinical tumor size is >3 cm

4. Non metastatic, M0 (according to clinical staging)

5. Luminal A patients ER-positive by immunohistochemistry (IHC) according to the following criteria (local assessment): Grade I or II AND ER-positive (=60%) AND Ki67 <20%

6. Her2-negative by IHC (score 0 or 1+) and/or fluorescent in situ hybridization (FISH)/chromogenic in situ hybridization (CISH) negative according to local assessment

7. CD8+ T Cell infiltration defined as >10% cells stained with anti-CD8 monoclonal antibody by IHC at the 3-week biopsy (applicable for inclusion in part 2 only)

8. Available tumor samples from baseline biopsy

9. World Health Organization (WHO)/Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at enrolment

10. Adequate organ and marrow function as defined below:

• Hemoglobin =9.0 g/dL

• Absolute neutrophil count =1.5 × 10?/L

• Platelet count =100 × 10?/L

• Serum bilirubin =1.5 × upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert's syndrome, who will be allowed in consultation with their physician

• Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) =2.5 × ULN

• Adequate renal function as determined by CKD-EPI formula (using actual body weight)

11. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures

12. Written informed consent obtained prior to performing any protocol-related procedures, including screening evaluations

Exclusion Criteria:

1. Inflammatory breast cancer

2. No prior exposure to immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-programmed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines

3. Any concurrent chemotherapy, investigational product (IP), biologic therapy for cancer treatment

4. Previous Radiotherapy treatment to more than 30% of the bone marrow;

5. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose

6. History of allogenic organ transplantation

7. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis or Crohn's disease], diverticulitis with the exception of diverticulosis, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea), systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome (granulomatosis with polyangiitis), Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc within the past 3 years prior to the start of treatment. The following are exceptions to this criterion:

• Patients with vitiligo or alopecia

• Patients with hypothyroidism (eg, following Hashimoto syndrome) stable on hormone replacement or psoriasis not requiring systemic treatment

8. Any condition that, in the opinion of the Investigator, would interfere with the evaluation of investigational product or interpretation of patient safety or study results, including ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events from investigational products, or compromise the ability of the patient to give written informed consent

9. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) =470 ms

10. History of active primary immunodeficiency

11. Known history of active tuberculosis

12. Active infection including hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)

13. Current or prior use of immunosuppressive medication within 14 days before the first dose. The following are exceptions to this criterion:

• Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra-articular injection)

• Systemic corticosteroids at physiologic doses not exceeding 10 mg/day of prednisone or its equivalent

• Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication)

14. Receipt of live, attenuated vaccine within 30 days prior to the first dose of IP.

Note: Patients, if enrolled, should not receive live vaccine during the study and up to 30 days after the last dose of IP

15. Known allergy or hypersensitivity to any medicinal product used in the trial or any excipient

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Estrogen Receptor Positive Tumor
• Hormone Antagonist
• Menopause

Intervention

Drug:
• Immune-attractant
The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) as immune-attractants combined with exemestane (25 mg daily).
• Durvalumab
Durvalumab (lymphocyte activation) will be administrated at a dose of 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months

Procedure:
• Biopsy
After three weeks (+/- 3 days) of immune-attractants, a tumor biopsy will be done. Patients who present >10% CD8+ cells in the tumor after 3 weeks will receive the Durvalumab

Locations

Country	Name	City	State
France	Centre Hospitalier cote Basque	Bayonne
France	Institut Bergonié	Bordeaux
France	Centre François Baclesse	Caen
France	Centre Hospitalier de Cahors	Cahors
France	Centre Hôspitalier de Cholet	Cholet
France	Centre George François Leclerc	Dijon
France	Institut Daniel Hollard Groupe Hôspitalier	Grenoble
France	Centre Oscar Lambret	Lille
France	CHU Limoges	Limoges
France	Centre Hospitalier Bretagne Sud	Lorient
France	Centre Léon Bérard	Lyon
France	Institut Paoli Calmettes	Marseille
France	Hôpital Saint Louis APHP	Paris
France	Institut Curie Site Paris	Paris
France	Centre Hospitalier Perpignan	Perpignan
France	Institut Jean Godinot	Reims
France	Institut Curie Hôpital René Huguenin	Saint Cloud
France	Centre Paul Strauss	Strasbourg
France	Institut Claudius Regaud	Toulouse
France	CHU Bretonneau - Centre Henry Kaplan	Tours
France	Gustave Roussy	Villejuif
Spain	ICO Badalona	Badalona
Spain	Hospital Clinic Barcelona	Barcelona
Spain	HU Vall Hebron	Barcelona
Spain	HU Arnau de Vilanova	Lleida
Spain	CIO Clara Campal	Madrid
Spain	HU Ramon y Cajal	Madrid
Spain	Hospital Clínico Universitario de Valencia	Valencia
Sweden	Sahlgrenska University Hospital	Gothenburg

Sponsors (2)

Lead Sponsor	Collaborator
UNICANCER	Breast International Group

Countries where clinical trial is conducted

France,  Spain,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	pathological Complete Response	Response at surgery	at time of surgery
Secondary	Number of CD8+ T cell	exam at biopsy and comparison between biopsy and Baseline biopsy rates	at biopsy (3 weeks)
Secondary	Clinical response	Clinical exam	after 6 months of Durvalumab
Secondary	Assessment of Ki67	measure of Ki67	at surgery
Secondary	Toxicities	Common terminology criteria for adverse events (CTC-AE) v4.03	1 year and 8 months
Secondary	Predictive value of Mutational load for efficacy of Durvalumab	exome sequencing on baseline samples	on baseline biopsy and blood samples
Secondary	Predictive value of PDL1 expression for the efficacy of Durvalumab	correlate Immune infiltrate intensity with the proportion of tumor cells expressing PD-L1 by Ventana SP263 assay	on baseline biopsy and biopsy at 3 weeks